The University of Dundee has reported results from two clinical trials indicating the use of a common, inexpensive diabetes drug metformin for heart and circulatory disease patients in the UK. Credit: British Heart Foundation.

The University of Dundee has reported results from two clinical trials indicating the use of common, inexpensive diabetes drug metformin for heart and circulatory disease patients in the UK.

Presented at the British Cardiovascular Society (BCS) Conference, the findings involved people living with high blood pressure-induced heart damage and aortic stenosis.

Related Company Profiles

View all

The first MET-REMODEL study investigated the effect of metformin on the heart and circulatory system over 12 months in coronary heart disease patients.

Funded by the British Heart Foundation (BHF), the trial demonstrated that the drug reversed the harmful thickening of the left ventricle and reduced high blood pressure and body weight in subjects who had suffered a heart attack.

The second Scotland’s Chief Scientist Office (CSO)-funded trial involved analysis of records of diabetic patients who also had aortic stenosis.

It was observed that patients treated with metformin were at less risk of death due to heart attack, stroke or heart failure, compared to those using other diabetes drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

British Heart Foundation associate medical director professor Jeremy Pearson said: “These studies provide real hope that metformin might help to reduce deaths from heart and circulatory diseases, which currently claim thousands of lives every year.

“Repurposing of drugs like metformin is a great example of how scientists can harness the power of medications which have more than one target in the body.”

Multiple research techniques such as big data and genomics were used to understand the mechanism behind metformin’s beneficial cardiovascular effects.

It was concluded that the drug is addressing insulin resistance and inflammation, which decreases the left ventricle’s size.